KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax (2024 - 2025)

Historic Long-Term Deferred Tax for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Q3 2025 value amounting to $957000.0.

  • Recursion Pharmaceuticals' Long-Term Deferred Tax changed N/A to $957000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $957000.0, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2024, which is N/A changed from last year.
  • Recursion Pharmaceuticals' Long-Term Deferred Tax amounted to $957000.0 in Q3 2025.
  • Recursion Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $2.0 million for Q1 2025, and its period low was $957000.0 during Q2 2025.